ScreenerHero

CSBRChampions Oncology, Inc.

NAS · US · Healthcare · Biotechnology · championsoncology.com
4.960USD+0.41%Mkt Cap: 68.91M $P/E: —

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implant…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap68.91M $
Enterprise Value71.82M $
Revenue (TTM)59.42M $
Gross Profit28.52M $
Net Income (TTM)-1.18M $
Revenue/Share4.296 USD
Last Price4.960 USD
Fiscal Year EndApr 2026
MR QuarterApr 2026
Employees214
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS15870P3073
Valuation
P/E (Trailing)—
P/E (Forward)51.80
PEG—
EV/EBITDA206.39
EV/Revenue1.21
P/S1.21
P/B18.24
EPS (TTM)-0.08
EPS (Forward)0.10
52W Range
4.8802% of range8.740
52W High8.740 USD
52W Low4.880 USD
Profitability
Gross Margin48.00%
Oper. Margin-3.77%
EBITDA Margin0.59%
Profit Margin-1.98%
ROE-29.83%
ROA-4.35%
Growth
Revenue Growth12.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.47M $
CapEx (TTM)564.00K $
FCF Margin-7.22%
FCF Yield-6.23%
Net Debt-274.00K $
Net Debt/EBITDA-0.79
Balance Sheet
Debt/Equity1.15
Current Ratio0.96
Quick Ratio0.91
Book Value/Sh0.2840 USD
Cash/Share0.3510 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateAug 12, 2015
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.89M
Float6.08M
Insiders26.66%
Institutions42.46%
Short Interest
Short Ratio8.5d
Short % Float1.12%
Short % Out.0.55%
Shares Short76.16K
Short (prev mo.)76.92K
Technical
SMA 505.797 (-14.4%)
SMA 2006.186 (-19.8%)
Beta0.41
S&P 52W Chg18.16%
Avg Vol (30d)10.05K
Avg Vol (10d)10.90K
Technical Indicators
RSI (14)35.2
MACD-0.2486
MACD Signal-0.2287
MACD Hist.-0.0199
BB Upper6.100 USD
BB Middle5.342 USD
BB Lower4.584 USD
BB Width28.37%
ATR (14)0.2951 USD
Vol Ratio (20d)0.72x